Video

Dr. Mascarenhas on the Role of Genetic Testing in MPNs

John O. Mascarenhas, MD, discusses the role of genetic testing in myeloproliferative neoplasms.

John O. Mascarenhas, MD, associate professor of medicine, hematology, and medical oncology at the Icahn School of Medicine at Mount Sinai, director of the Adult Leukemia Program, and leader of Clinical Investigation within the Myeloproliferative Disorders Program at Mount Sinai, and a member of the Tisch Cancer Institute, discusses the role of genetic testing in myeloproliferative neoplasms (MPNs).

At most cancer centers, genetic testing is typically performed at the time of diagnosis or if a patient’s diagnosis changes, explains Mascarenhas. At initial diagnosis, next-generation sequencing (NGS) may be performed if the patient’s bone marrow biopsy shows that their blood is not able to be aspirated. Physician preference often determines which NGS panel is utilized, Mascarenhas says.

Typically, NGS panels test for myeloid-associated genetic mutations commonly found in patients with myelodysplastic syndrome, MPNs, or acute myeloid leukemia, says Mascarenhas. Moreover, identification of driver mutations, such as JAK2, CALR, and MPL, can confer prognostic significance. Additionally, the absence of these driver mutations indicates triple-negative disease, which is also prognostic.

Currently, genetic testing results do not have therapeutic implications, Mascarenhas explains. However, immunotherapeutic agents directed toward calreticulin are in development as the gene codes for a potentially targetable cell surface mutation. Ultimately, MPNs are complex diseases so prognostically significant subclonal mutations are used in risk stratification, concludes Mascarenhas.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma
Video

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

Jun 19th 2025 - Jul 25th 2025

online-activity
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity